PolyPid Ltd. (PYPD)
- Previous Close
2.8100 - Open
3.2800 - Bid --
- Ask --
- Day's Range
2.8000 - 3.2800 - 52 Week Range
2.3000 - 4.7060 - Volume
93,283 - Avg. Volume
17,467 - Market Cap (intraday)
29.554M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.2400 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.33
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
www.polypid.comRecent News: PYPD
View MorePerformance Overview: PYPD
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PYPD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PYPD
View MoreValuation Measures
Market Cap
28.64M
Enterprise Value
29.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
332.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-86.72%
Return on Equity (ttm)
-853.05%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.84M
Diluted EPS (ttm)
-4.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
8.04M
Total Debt/Equity (mrq)
10,265.12%
Levered Free Cash Flow (ttm)
--